Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Franck Pagès,Thierry André,Julien Taieb,Dewi Vernerey,Julie Henriques,Christophe Borg,Florence Marliot,Rim Ben Jannet,Christophe Louvet,Laurent Mineur,Jaafar Bennouna,Jérôme Desramé,Roger Faroux,Alex Duval,Pierre Laurent-Puig,Magali Svrcek,Fabienne Hermitte,Aurélie Catteau,Jérôme Galon,Jean-François Emile

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

2020

10Background: In stage III colon cancer patients treated with CAPOX, 3 months of therapy was as effective as 6 months. It was not the case for those receiving mFOLFOX6. We assessed the prognostic a...

Keywords:

Internal medicine
Stage III Colon Cancer
Oncology
Medicine
Pathology
Cohort study
predictive value

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations